|1.||Griffiths, Roland R: 3 articles (02/2010 - 09/2005)|
|2.||Richards, Bethan L: 2 articles (09/2012 - 01/2012)|
|3.||Buchbinder, Rachelle: 2 articles (09/2012 - 01/2012)|
|4.||Whittle, Samuel L: 2 articles (09/2012 - 01/2012)|
|5.||Bista, Sabin R: 2 articles (01/2012 - 08/2010)|
|6.||Chowdhuri, Susmita: 2 articles (01/2012 - 08/2010)|
|7.||Casey, Kenneth R: 2 articles (01/2012 - 08/2010)|
|8.||Kristo, David A: 2 articles (01/2012 - 08/2010)|
|9.||Zak, Rochelle S: 2 articles (01/2012 - 08/2010)|
|10.||Lamm, Carin I: 2 articles (01/2012 - 08/2010)|
|1.||Sleep Initiation and Maintenance Disorders (Insomnia)
05/01/1983 - "Overall, triazolam is an effective and safe compound for the symptomatic treatment of insomnia complaints."
08/01/1981 - "Triazolam: a review of its pharmacological properties and therapeutic efficacy in patients with insomnia."
08/01/1993 - "The authors examined sleep improvement in subjects with primary insomnia who received triazolam plus behavioral therapy (N = 8) or triazolam plus sleep-related information (N = 7). "
11/01/1983 - "A double-blind crossover study in 53 psychiatric outpatients compared the safety and efficacy of triazolam and placebo in relieving insomnia refractory to treatment with a tricyclic antidepressant. "
01/01/2002 - "Sixty-four healthy men and women with and without insomnia (aged 21-55 years) were given an opportunity to self-administer placebo or triazolam (0.25 mg) capsules (single-choice method - available capsule or no capsule) before sleep in three separate studies. "
04/01/2006 - "Our data indicate that oral triazolam is beneficial in decreasing pain and anxiety associated with self-activated atrial defibrillation. "
01/01/1998 - "Triazolam improves sleep but fails to alter pain in TMD patients."
08/01/1997 - "Sublingual triazolam resulted in significantly less anxiety and pain at 15 minutes intraoperatively than both oral triazolam and placebo (p < 0.05). "
04/01/2006 - "Decreasing pain and anxiety associated with patient-activated atrial shock: a placebo-controlled study of adjunctive sedation with oral triazolam."
04/01/2006 - "Triazolam reduced mean pre-shock anxiety (t= 2.98, df = 14, P = 0.01) and shock-related pain (t= 2.74, df = 13, P = 0.01) and intensity (t= 2.64, df = 13, P = 0.018) relative to placebo. "
|3.||Substance-Related Disorders (Drug Abuse)
01/01/2001 - "In the third, rats were treated chronically three daily doses of triazolam (started by 0.25 mg/kg and increased by time to 0.5 mg/kg) for 20 days, simulating a form of drug abuse. "
01/01/2000 - "In the third, rats were treated chronically with three daily doses of Triazolam (started with 0.25 mg/kg and increased by time to 0.5 mg/kg) for 20 days, representing a form of drug abuse. "
02/01/1995 - "The two subjects who did not self-administer triazolam in preference to placebo also had lesser histories of drug dependence. "
07/01/1999 - "The present study compared the acute subject-rated effects, performance-impairing effects, and abuse potential of zaleplon and triazolam, a triazolobenzodiazepine hypnotic, in 14 healthy volunteers with histories of drug abuse. "
01/01/2000 - "In conclusion, chronic single daily dose treatment (representing normal use) produces tolerance to Triazolam effects on brain GABA levels, while chronic three daily doses administration (akin to drug abuse) causes a fall in GABA levels."
04/01/2006 - "The main objective of the present study was to determine whether triazolam improved patient perception of the shock experience or altered patient memory of shock discomfort relative to placebo. "
04/01/2006 - "Similarly, participants recalled less discomfort the morning after shock with triazolam than with placebo (t= 2.82, df = 11, P = 0.017). "
07/01/2004 - "In contrast, triazolam only decreased errors and enhanced acquisition in the presence of concurrent response-independent tail shock when compared to saline administration under this condition. "
02/01/1999 - "Six monkeys discriminated 0.1 mg/kg of triazolam from vehicle under a fixed-ratio 5 (FR 5) schedule of stimulus-shock termination (SST). "
01/01/1995 - "Triazolam (0.01-0.1 mg/kg, s.c.), administered before training, attenuated the suppression of motility in the conditioned fear stress task in a dose-dependent manner, without affecting the sensitivity to an electric foot shock. "
|5.||Chronic Obstructive Pulmonary Disease (COPD)
10/01/1988 - "We conclude that single-night use of triazolam improved the quality and duration of sleep in patients with chronic obstructive pulmonary disease. "
06/01/1993 - "Effects of zolpidem and triazolam on sleep and respiration in mild to moderate chronic obstructive pulmonary disease."
10/01/1988 - "Effect of triazolam on sleep and arterial oxygen saturation in patients with chronic obstructive pulmonary disease."
10/01/1988 - "We compared the effects of a placebo with 0.125 and 0.25 mg of triazolam (Halcion) on sleep quality, oximetry, and respiratory events during sleep in ten stable outpatients with chronic obstructive pulmonary disease. "
03/01/1990 - "Comparison of zolpidem (Z), triazolam (T), and flunitrazepam (F) effects on arterial blood gases and control of breathing in patients with severe chronic obstructive pulmonary disease (COPD)."